5-甲氧基-2-[(4-甲氧基-3,5-二甲基-2-吡啶基)-甲基]-3H-苯并咪唑钠盐 | 161796-77-6

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-甲氧基-2-[(4-甲氧基-3,5-二甲基-2-吡啶基)-甲基]-3H-苯并咪唑钠盐
• 英文名称: r-Omeprazole
• CAS: 161796-77-6
• 化学式: C17H19N3NaO3S
• 分子量: 368.4
• InChiKey: HVAJOLFRLWQQQL-GJFSDDNBSA-N

物化性质

• 熔点：
  242-245°C
• 溶解度：
  可溶于二甲基亚砜、水

计算性质

• 辛醇/水分配系数(LogP)：
  2.52
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  96.3
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 安全说明：
  S24/25
• 海关编码：
  29339900
• WGK Germany：
  3

文献信息

• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties
  申请人：Gant G. Thomas

  公开号：US20070082929A1

  公开（公告）日：2007-04-12

  Chemical syntheses and medical uses of novel inhibitors of the gastric H + , K + -ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.

  描述了用于治疗和/或管理十二指肠溃疡、胃灼热、酸反流、其他由胃酸分泌介导的疾病以及牛皮癣的新型胃H+、K+-ATP酶抑制剂的化学合成和医学用途。
• Novel process for the preparation of esomeprazole and salts thereof
  申请人：Wang Fan

  公开号：US20070287839A1

  公开（公告）日：2007-12-13

  A novel process for the preparation of omeprazole and its enantiomers, such as esomeprazole, as well as the preparation of related 2-(2-pyridinylmethyl-sulphinyl)-1H-benzimidazoles, including pantoprazole, lansoprazole and rabeprazole, as recemates or single enantiomers, and their alkali or alkaline salts has been developed. The novel process involves the surprising discovery that protection of the free-base benzimidazole sulfoxide (e.g. omeprazole or esomeprazole), by reaction with an alkyl, aryl or aralkyl chloroformate following oxidation of the corresponding sulfide, eliminates the need for its direct isolation. Subsequent removal of the protecting group with a solution of alkali or alkaline earth alkoxide in a C1-C4 alcohol directly provides the corresponding salt. By eliminating the need to handle the free-base benzimidazole sulfoxide, this advantageous procedure provides increased chemical yields over processes described in the art.

  一种新型制备奥美拉唑及其对映体（如左旋奥美拉唑）以及相关的2-(2-吡啶甲基-亚砜基)-1H-苯并咪唑类化合物（包括泮托拉唑、兰索拉唑和雷贝拉唑）的方法已经开发出来。这种新型方法涉及到一个惊人的发现，即通过与烷基、芳基或芳基氯甲酸酯反应保护游离基苯并咪唑亚砜氧化物（例如奥美拉唑或左旋奥美拉唑），随后通过对应硫醚的氧化消除了对其直接分离的需求。随后，通过使用C1-C4醇中碱或碱土金属烷氧化物溶液去除保护基，直接得到相应的盐。通过消除处理游离基苯并咪唑亚砜氧化物的需求，这种优势的程序提供了比文献中描述的工艺更高的化学产率。
• [EN] CRYSTALLINE FORMS OF RABEPRAZOLE SODIUM<br/>[FR] FORMES CRISTALLINES DE RABEPRAZOLE SODIQUE
  申请人：REDDYS LAB LTD DR

  公开号：WO2003082858A1

  公开（公告）日：2003-10-09

  The present invention relates to novel polymorphic forms of Rabeprazole sodium. The present invention also relates to methods of making polymorphic forms of Rabeprazole sodium. Achiphex7 (Rabeprazole sodium) is an inhibitor of the gastric proton pump. It causes dose-dependant inhibition of acid secretion and is useful as an antiulcer agent. The chemical designation of Rabeprazole sodium is 2-[[[4-(3-methoxypropoxy)-3 methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole sodium. It may be represented by Formula (1).

  本发明涉及拉贝拉唑钠的新型多晶型形式。本发明还涉及制备拉贝拉唑钠的多晶型的方法。Achiphex7（拉贝拉唑钠）是胃质子泵抑制剂。它能引起剂量依赖性的酸分泌抑制，并且可用作抗溃疡剂。拉贝拉唑钠的化学名称为2-[[[4-(3-甲氧基丙氧基)-3-甲基-2-吡啶基]-甲基]亚砜基]-1H-苯并咪唑钠。它可以用公式（1）表示。